Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Key Clinical Milestones
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions, will participate in a fireside chat at the Jefferies Global Healthcare Conference, highlighting its Phase 3 and Phase 2 programs for major depressive disorder and generalized anxiety disorder.
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website.
The company’s participation underscores its progress in advancing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder.
The Jefferies Global Healthcare Conference is a key event for the healthcare investment community, and Helus Pharma’s presence signals its commitment to addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, the company aims to improve the treatment landscape through NSAs that provide durable improvements in mental health.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The latest news and updates are available in the company’s newsroom at https://ibn.fm/HELP.